FDA approves a CRISPR-based medicine for treatment of sickle cell disease

Significance of the approval

• Widely seen as historic: first FDA‑approved CRISPR gene‑editing medicine, potentially opening the door for many monogenic disease treatments.
• Commenters expect major long‑term impact on cancer, inherited disorders, and possibly broader body modification, though timelines are debated.

How the therapy works

• Ex vivo approach: harvest patient’s stem cells, edit them with CRISPR (via plasmid electroporation in this case), expand them, then ablate existing bone marrow with chemotherapy and reinfuse edited cells.
• Strategy for sickle cell: reactivate fetal hemoglobin (a fetal HBB gene variant that is unaffected by the sickle mutation) rather than directly repairing the mutated adult gene.
• This avoids in‑body (“in vivo”) editing challenges, but is still described as radical and burdensome.

Risks and side effects

• A related therapy (Lyfgenia) received a black‑box warning after trial patients developed blood cancers; studies attribute this to the chemotherapy conditioning, not the gene edit itself.
• Some fear media and public may incorrectly blame “gene therapy” broadly, harming the field’s reputation.
• Others note ongoing research into chemo‑free conditioning (e.g., immunotherapy or radiation‑free approaches), but those would likely require new approvals.

Costs, pricing, and health economics

• Casgevy is priced around $2.2M; another similar therapy is cited at $3.1M.
• Analyses suggest such treatments are cost‑effective in the ~$1.35–$2.05M range, comparable to current lifetime management costs for sickle cell in the US ($1.6–$1.7M).
• Debate over whether prices will meaningfully fall: some expect “version 1” to be the most expensive and foresee process automation and competition; others note biologics often stay expensive and cannot go generic as easily as small molecules.

Access and insurance structures

• Some argue that because untreated sickle cell is already very costly and debilitating, insurers and taxpayers have strong incentives to cover curative therapies.
• Others raise moral questions: is spending millions on one severely ill patient justified when the same money could help many others?
• There’s contention over whether US patients are uniquely at risk of medical bankruptcy versus enjoying faster access compared to slower, more budget‑constrained national systems elsewhere.

Ethics and future body editing

• Strong support in the thread for bodily autonomy and “max body‑editing,” including cosmetic changes and designer bodies; a minority worries about social and safety implications (e.g., bioterror, Gattaca‑like inequality).
• One view holds it’s unethical to deny people the option to repair or enhance their bodies; another highlights resource limits and trade‑offs.

Evolutionary context of sickle cell

• Multiple comments explain that the sickle mutation persists because it is recessive and carriers (without full disease) gain protection against malaria, giving a net evolutionary advantage in malaria‑endemic regions.
• Some argue that with modern malaria treatments and vaccines, this tradeoff is no longer desirable.

CRISPR beyond human therapy

• Mention of CRISPR‑edited potatoes (e.g., higher beta carotene, altered sugar content) as an example of parallel progress in agriculture.
• Side discussion on nutritional impacts, food safety, and even speculative ideas like altering human digestion.

Off‑target editing concerns

• A question is raised about whether CRISPR off‑target effects are “solved”; responses suggest they remain a known risk to monitor, but are managed through careful design and ex vivo selection, not eliminated.
• No clear consensus in the thread on how fully this issue is controlled; status is effectively “improving but not solved.”